Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Platinum-resistant Ovarian Cancer · Platinum-refractory Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · High-grade Serous Ovarian Cancer · Endometrioid Ovarian Cancer · Ovarian Clear Cell Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9.7
3 insiders sold shares within a month
Since Nov 3, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 186 (planned)
- Started
- Aug 31, 2022
- Main results expected
- Dec 2026
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)
Measured over: From date of randomization up to 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9.7, since 2026-11-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05281471 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC